Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

725.57 -6.63 (-0.91%)
Streaming Delayed Price Updated: 12:33 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Dividend Legends: 3 Stocks With Over 100 Years of Payouts
Dividend payers are companies that have stood the test of time and these dividend stocks with 100+ years of payouts lead them all. 
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
These three large-cap blue-chip growth stocks are certainly worth considering as core portfolio holdings in this current environment. 
Via InvestorPlace
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
Explore the dynamics of money-maker stocks in 2024, which are fueled by AI advancements and robust economic growth. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1... 
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course. 
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits. 
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of... 
Via TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
Capturing Consumer Spending on Health Care with XLV 
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
SPDR ETF Report For Friday, April 19
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, April 19. 
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Investors should not ignore these highly rated stocks to buy now because they deserve their reputation as the market heats up. 
Via InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder. 
Via InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
These stocks have taken different paths to where they are today, but both have been exceptional investments. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.